A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients
Status:
Suspended
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
Patients with locally recurrent BRCA1-like, HER2-negative breast cancer that cannot be
treated with curative intent by local treatment (surgery, radiotherapy +/- hyperthermia) or
patients with metastatic BRCA1-like, HER2-negative breast cancer that have received a maximum
of one prior line of treatment for incurable disease will be treated with Niraparib until
disease progression